34
Participants
Start Date
February 28, 2009
Primary Completion Date
September 30, 2015
Study Completion Date
September 30, 2015
Intravenous Rituximab
"Rituximab Therapy \[27 Patients\]~* Rituximab 1 gm IV on Treatment Day 1~* Rituximab 1 gm IV on Treatment Day 15~* Rituximab 1 gm IV on Treatment Day 168~* Rituximab 1 gm IV on Treatment Day 182"
ACE/ARB
ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of \<130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
Omega-3 Fatty Acid Fish Oil Supplement
Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
Columbia University Medical Center, New York
University of North Carolina, Chapel Hill, Chapel Hill
Mayo Clinic, Rochester
Stanford University, San Francisco
The University of Ohio, Columbus
Lead Sponsor
Collaborators (2)
Ohio State University
OTHER
Stanford University
OTHER
University of North Carolina, Chapel Hill
OTHER
Columbia University
OTHER
Genentech, Inc.
INDUSTRY
Biogen
INDUSTRY
Mayo Clinic
OTHER